Developing new cancer immunotherapy agents targeting BTN3A1
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy
This study is exploring new ways to boost the immune system's ability to fight cancer by developing special compounds that help activate a protein called BTN3A1, which could lead to better treatments for more cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Storrs NIH-funded |
| Lab location | 1 site (Storrs-Mansfield, United States) |
| Project ID | NIH-11067751 on NIH RePORTER |
What this research studies
This research focuses on creating and testing new compounds that activate the BTN3A1 protein, which plays a crucial role in enhancing the immune response against cancer. By stimulating specific types of T cells, the goal is to improve the effectiveness of cancer immunotherapy. The researchers are synthesizing novel ligands with better stability and effectiveness in laboratory and animal models, aiming to find treatments that can work for a broader range of cancer patients. The approach involves innovative drug design to enhance the properties of these compounds for better therapeutic outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have not responded well to existing immunotherapies or those with specific types of cancer that may benefit from enhanced T cell activation.
Not a fit: Patients with cancers that are not influenced by T cell activation or those who have contraindications to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for cancer immunotherapy, indicating that this approach could lead to significant advancements.
Where this research is happening
Storrs-Mansfield, United States
- University of Connecticut Storrs — Storrs-Mansfield, United States (Active)
Researchers
- Principal investigator: Wiemer, Andrew J — University of Connecticut Storrs
- Study coordinator: Wiemer, Andrew J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.